The Lymphoma Channel: Viral Lymphoma

Explore the latest updates and expert interviews

The Lymphoma Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company), Takeda, Karyopharm Therapeutics and MorphoSys. The supporters have no influence over the production of the content.

View Lymphoma Overview Page
Oral nanatinostat and valganciclovir for EBV-associated lymphomas 1:47
Oral nanatinostat and valganciclovir for EBV-associated lymphomas
Pierluigi Porcu
Dutch HOVON lymphoma study group update 2:36
Dutch HOVON lymphoma study group update
Pieternella Lugtenburg • 20 Jun 2019
Viral lymphomas: risk factors and treatments 8:24
Viral lymphomas: risk factors and treatments
Catherine Bollard et al. • 21 Sep 2018
Cellular therapy and drug access for viral lymphomas 9:57
Cellular therapy and drug access for viral lymphomas
Catherine Bollard et al. • 21 Sep 2018

The Lymphoma Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company), Takeda, Karyopharm Therapeutics and MorphoSys.

The supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.

VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals